ReviewClinical epigenetics2025
The OGG1 Ser326Cys polymorphism: molecular mechanisms of disease susceptibility and precision medicine applications.
Review in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The relationship between DNA damage and repair and the occurrence and development of disease.Frontiers in genetics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
DNA molecules are susceptible to reactive oxygen species (ROS) attack leading to oxidative damage, of which 8-oxoguanine (8-oxoG) is a core oxidative marker. OGG1 acts as a DNA repair enzyme and maintains genomic stability by specifically repairing 8-oxoG through the base excision repair (BER) pathway. The Ser326Cys polymorphism significantly reduces enzyme activity and potentially impacts phosphorylation-mediated subcellular localization dynamics and epigenetic regulatory networks, thereby potentially exacerbating genomic instability. In this review, we analyzed the association between the OGG1 Ser326Cys polymorphism and different diseases, such as risk, platinum-based chemotherapy sensitivity, and radiotherapy toxicity in cancer. In neurodegenerative disorders, the Cys326 type leads to the accumulation of 8-oxoG in neurons and accelerates CAG triplet repeat amplification. In metabolic disorders, its insufficient repair may trigger β-cell dysfunction, which increases the risk of type 2 diabetes mellitus. Finally, we integrated multiomics data and proposed a genotype-based precision intervention strategy to provide a theoretical basis for disease risk prediction, personalized therapy, and novel targeted drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.